How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/anti-ige-therapy-xolair.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

ANTI-IGE THERAPY (XOLAIR) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ANTI-IGE THERAPY (XOLAIR) (ANTI-IGE THERAPY (XOLAIR)) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anti-IgE monoclonal antibody. Area: Immunology / Allergy / Respiratory.

marketed Anti-IgE monoclonal antibody Immunoglobulin E (IgE) Immunology / Allergy / Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

ANTI-IGE THERAPY (XOLAIR) (ANTI-IGE THERAPY (XOLAIR)) — Children's Hospital of The King's Daughters. Xolair (omalizumab) is a monoclonal antibody that binds to circulating IgE, preventing it from interacting with high-affinity IgE receptors on mast cells and basophils.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ANTI-IGE THERAPY (XOLAIR) TARGET	ANTI-IGE THERAPY (XOLAIR)	Children's Hospital of The King's Daughters	marketed	Anti-IgE monoclonal antibody	Immunoglobulin E (IgE)
Xolair injections	Xolair injections	University of California, Los Angeles	marketed	Anti-IgE monoclonal antibody	Immunoglobulin E (IgE)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anti-IgE monoclonal antibody class)

Children's Hospital of The King's Daughters · 1 drug in this class
University of California, Los Angeles · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ANTI-IGE THERAPY (XOLAIR) — Competitive Intelligence Brief. https://druglandscape.com/ci/anti-ige-therapy-xolair. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab